Fig. 5
From: Anti-EGFR conjugated nanoparticles to deliver Alpelisib as targeted therapy for head and neck cancer
Antiproliferative effect induced by free Alpelisib and Alpelisib conjugated into nanoparticles in the indicated cell lines at 72 h. a Sensitivity of the different cell lines (measured by XTT assay) to free Alpelisib. The inhibitory concentration 50 (IC50) for each cell line is shown. Calculation of the concentrations IC50 based on a nonlinear regression curve fit (log(inhibitor) vs. normalized response, variable slope). Cell viability of b Cal33, c Cal 27, and d FaDu cells incubated for 72 h with different concentrations of free Alpelisib (as in a) or with equivalent amounts of the drug loaded into NP or ACNP. IC50 for each condition is shown. Mean ± SEM. Curve fit for: NP-Alpelisib or ACNP-Alpelisib versus free drug, pVal < 0.0001; NP-Alpelisib versus ACNP-Alpelisib, pVal > 0.5 (not significant). Extra-sum-of-squares F test